Pharmaceutical Drug Development Annual Review - 2024

This report investigates the year 2024 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.

Scope

This 46-page report gives important, expert insight you won’t find in any other source. 21 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines. This report is required reading for:

• Investors that want to understand past trends impacting the biopharmaceutical industry as well as identifying companies to invest in
• Companies that are interested in entering the biopharmaceutical space and where best to focus on
• Large pharma companies with investment groups or BD teams looking to see which companies lead the industry in the past and how they led
• Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities

Reasons to Buy

• Insights on how drug development in 2024 may impact future approvals
• Insights on how drug approvals in 2024 may impact future drug development and approval trends
• Sales and regulatory-based insights into 2024 covering various drugs and companies